Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET
NEWARK, Calif.--(BUSINESS WIRE)--Apr. 24, 2019--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the company will
release first quarter 2018 financial results on Wednesday, May 8, 2019
after the close of market. Revance will host a corresponding conference
call and a live webcast at 1:30 p.m. PT/4:30 p.m. ET on the same day to
discuss the results and provide a business and pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 5753548; or from the
webcast link in the investor relations section of the company’s website
A replay of the call will be available beginning May 8, 2019 at 4:30
p.m. PT/7:30 p.m. ET to May 9, 2019 at 4:30 p.m. PT/7:30 p.m. ET. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and reference
conference ID: 5753548. The webcast will be available in the investor
relations section on the company's website for 30 days following the
completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary peptide
excipient technology to create novel, differentiated therapies. The
company’s lead compound, DaxibotulinumtoxinA for Injection (DAXI), is in
clinical development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. DAXI has the
potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005880/en/
Source: Revance Therapeutics, Inc.
Revance Therapeutics, Inc.:
Laurence Watts, 619-916-7620
Nadine Tosk, 504-453-8344